SCHEMBL2926415

SCHEMBL2926415

CC(C)(C)OC(=O)N1CCN(Cc2ccc(C(O)c3ccc(Cl)cc3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 1/20 0.60
EGLN1 Q9GZT9 1/20 0.60
PLA2G7 Q13093 1/20 0.57
MGLL Q99685 1/20 0.57
ABHD6 Q9BV23 1/20 0.57
POLB P06746 1/20 0.55
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HTT P42858 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TP53 P04637 1/20 0.49
THRB P10828 1/20 0.49
ALDH1A1 P00352 2/20 0.49
STS P08842 1/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536182 0.91 VEGFA (0.68) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL32667348 0.88 VEGFA (0.64) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL2932582 0.85 VEGFA (0.62) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL22420328 0.85 KDM4E (0.54) VEGFAEGLN1POLBMEN1KMT2A
SCHEMBL18459829 0.83 HTT (0.51) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL18459273 0.83 HTT (0.51) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL7119173 0.82 MEN1 (0.54) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL1978087 0.81 MEN1 (0.56) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL19700728 0.81 VEGFA (0.49) VEGFAEGLN1PLA2G7MGLLABHD6
SCHEMBL2363123 0.81 VEGFA (0.56) VEGFAEGLN1PLA2G7MGLLABHD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed
EP-2121616-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS Campiani, Giuseppe (IT) 2009-11-25 EP disclosed
WO-2008101891-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 VEGFA 4470/4885EGLN1 1146/4885PLA2G7 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.